Alimentiv, formerly Robarts Clinical Trials, announced a major rebranding to reflect the company’s continued growth as a specialized global gastrointestinal (GI) contract research organization (CRO).
Jeff Smith, CEO, made the announcement at Alimentiv’s inaugural live stream event featuring keynote speakers William Sandborn, Professor of Medicine, Chief, Division of Gastroenterology, Vice Chair for Clinical Operations, Department of Medicine, Director, UCSD IBD Center, UC San Diego Health System and Duncan Hall, CEO, and Founder of TRI - The RBQM Company and Brian G. Feagan, MD, FRCPC - Senior Scientific Director at Alimentiv and Professor of Medicine at Western University.
Alimentiv will continue its work in clinical trials, imaging, and precision medicine for GI diseases. The Alimentiv CRO will operate under the Alimentiv Health Trust - a unique, social enterprise structure whose purpose is to Transform Human Health by building enduring businesses that prioritize research and the best interests of its employees. The CRO will continue to fund academic research on a global scale.
“We are excited to move forward as Alimentiv. Under the Alimentiv Health Trust, we remain a commercial venture driven by purpose, putting people first and profitable growth. We are excited about our expansion to new markets and the opportunity we have to continue to prioritize our vision of building a leading GI clinical drug development organization that accelerates discovery through the delivery of our range of services and continued investment in academic research,” said Jeff Smith, CEO of Alimentiv. “Operating within the Trust our business has the privilege to grow with a 100-year perspective, where the measure of success is not the value created by an exit, but rather the value created by fulfilling our purpose.”